GlaxoSmithKline Settles Majority of Avandia Lawsuits Ahead of FDA Panel Vote
GlaxoSmithKline, whose diabetes drug Avandia is undergoing a safety review by the FDA, has agreed to pay about $460 million to resolve about 10,000 lawsuits from users of the drug, which can allegedly cause heart attacks and strokes. Continue reading GlaxoSmithKline Settles Majority of Avandia Lawsuits Ahead of FDA Panel Vote GlaxoSmithKline Settles Majority of Avandia Lawsuits Ahead of FDA Panel Vote originally appeared on DailyFinance on Tue, 13 Jul 2010 17:05:00. Filed Under: Company News , Health Care , GlaxoSmithKline Permalink | Tweet this! | Comments
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here